BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 9647606)

  • 1. Summary of clinical trials with zafirlukast.
    Calhoun WJ
    Am J Respir Crit Care Med; 1998 Jun; 157(6 Pt 2):S238-45; discussion S245-8. PubMed ID: 9647606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Summary of clinical trials with zafirlukast.
    Calhoun WJ
    Am J Respir Crit Care Med; 1998 Jun; 157(6 Pt 1):S238-46. PubMed ID: 9620946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single dose of zafirlukast reduces LTD4-induced bronchoconstriction in patients on maintenance inhaled corticosteroid therapy.
    Smith LJ; Hanby LA; Lavins BJ; Simonson SG
    Ann Allergy Asthma Immunol; 1998 Jul; 81(1):43-9. PubMed ID: 9690572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zafirlukast: the first leukotriene-receptor antagonist approved for the treatment of asthma.
    Kelloway JS
    Ann Pharmacother; 1997 Sep; 31(9):1012-21. PubMed ID: 9296243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The leukotriene receptor antagonist zafirlukast inhibits sulfur dioxide-induced bronchoconstriction in patients with asthma.
    Lazarus SC; Wong HH; Watts MJ; Boushey HA; Lavins BJ; Minkwitz MC
    Am J Respir Crit Care Med; 1997 Dec; 156(6):1725-30. PubMed ID: 9412547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Zafirlukast (Accolate): a review of its pharmacological and clinical profile].
    Murata Y; Sugimoto O
    Nihon Yakurigaku Zasshi; 2002 Apr; 119(4):247-58. PubMed ID: 11979731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of the leukotriene receptor antagonist zafirlukast on neurokinin A-induced bronchoconstriction in patients with asthma--A comparison with leukotriene D4 induced broncoconstriction.
    Schelfhout V; Van De Velde V; Pauwels R; Joos G
    Pulm Pharmacol Ther; 2008; 21(2):276-84. PubMed ID: 17611132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zafirlukast: an update of its pharmacology and therapeutic efficacy in asthma.
    Dunn CJ; Goa KL
    Drugs; 2001; 61(2):285-315. PubMed ID: 11270943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors.
    Drazen J
    Am J Respir Crit Care Med; 1998 Jun; 157(6 Pt 2):S233-7; discussion S247-8. PubMed ID: 9647605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacology of leukotriene receptor antagonists.
    Aharony D
    Am J Respir Crit Care Med; 1998 Jun; 157(6 Pt 2):S214-8; discussion S218-9, S247-8. PubMed ID: 9647602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of asthma with zafirlukast. Clinical experience and tolerability profile.
    Spector SL
    Drugs; 1996; 52 Suppl 6():36-46. PubMed ID: 8941502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zafirlukast. A review of its pharmacology and therapeutic potential in the management of asthma.
    Adkins JC; Brogden RN
    Drugs; 1998 Jan; 55(1):121-44. PubMed ID: 9463793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of zafirlukast on cough reflex sensitivity in asthmatics.
    Dicpinigaitis PV; Dobkin JB
    J Asthma; 1999 May; 36(3):265-70. PubMed ID: 10350223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zafirlukast for asthma.
    Med Lett Drugs Ther; 1996 Dec; 38(990):111-2. PubMed ID: 8988153
    [No Abstract]   [Full Text] [Related]  

  • 15. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial.
    Suissa S; Dennis R; Ernst P; Sheehy O; Wood-Dauphinee S
    Ann Intern Med; 1997 Feb; 126(3):177-83. PubMed ID: 9027267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leukotriene E(4)-induced persistent eosinophilia and airway obstruction are reversed by zafirlukast in patients with asthma.
    Laitinen A; Lindqvist A; Halme M; Altraja A; Laitinen LA
    J Allergy Clin Immunol; 2005 Feb; 115(2):259-65. PubMed ID: 15696079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lung function improvement in smokers suffering from COPD with zafirlukast, a CysLT(1)-receptor antagonist.
    Cazzola M; Boveri B; Carlucci P; Santus P; DiMarco F; Centanni S; Allegra L
    Pulm Pharmacol Ther; 2000; 13(6):301-5. PubMed ID: 11061985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the cysteinyl leukotriene receptor antagonists pranlukast and zafirlukast on tracheal mucus secretion in ovalbumin-sensitized guinea-pigs in vitro.
    Liu YC; Khawaja AM; Rogers DF
    Br J Pharmacol; 1998 Jun; 124(3):563-71. PubMed ID: 9647482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and duration of action of the antileukotriene zafirlukast on cold air-induced bronchoconstriction.
    Richter K; Jörres RA; Magnussen H
    Eur Respir J; 2000 Apr; 15(4):693-9. PubMed ID: 10780761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group.
    Fish JE; Kemp JP; Lockey RF; Glass M; Hanby LA; Bonuccelli CM
    Clin Ther; 1997; 19(4):675-90. PubMed ID: 9377612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.